SVRA
SVRA clinical trials: Savara Inc
Every trial on ClinicalTrials.gov where Savara Inc is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 11
- Trials linked
- 11
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
SVRA on the catalyst calendar · SVRA registry changes
- Primary completion Nov 30, 2023ActualPhase 3NCT04544293Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)Savara Inc. · Autoimmune Pulmonary Alveolar ProteinosisActive, not recruitingSVRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT06546098Molgramostim Nebulizer Solution Expanded Access Program ProtocolSavara Inc. · Autoimmune Pulmonary Alveolar ProteinosisAvailableSVRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 3NCT06431776Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).Savara Inc. · Autoimmune Pulmonary Alveolar ProteinosisRecruitingSVRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 14, 2021ActualPhase 3NCT03482752Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar ProteinosisSavara Inc. · Autoimmune Pulmonary Alveolar ProteinosisTerminatedSVRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 15, 2019ActualPhase 2NCT03421743Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) InfectionSavara Inc. · Mycobacterium Infections, NontuberculousCompletedSVRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 19, 2019ActualPhase 2NCT02702180Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar ProteinosisSavara Inc. · Autoimmune Pulmonary Alveolar ProteinosisCompletedSVRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2, 2020ActualPhase 2NCT03597347Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial InfectionSavara Inc. · Mycobacterium Infections, NontuberculousTerminatedSVRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 28, 2020ActualPhase 3NCT03181932AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic FibrosisSavara Inc. · MRSACompletedSVRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2014ActualPhase 2NCT01746095Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis PatientsSavara Inc. · Cystic FibrosisCompletedSVRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2015ActualPhase 1NCT02468908Inhaled Molgramostim (rhGM-CSF) in Healthy Adult SubjectsSavara Inc. · Pulmonary Alveolar ProteinosisCompletedSVRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2012ActualPhase 1NCT01537666Inhaled Vancomycin Tolerability, Safety and PharmacokineticsSavara Inc. · HealthyCompletedSVRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 11 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner